Akorn Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
50
About the Report
About the Report
Summary
Akorn Inc (Akorn) develops, manufactures, and commercializes generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its products in both sterile and non-sterile dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn caters to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. The company has manufacturing facilities in India and the US. It operates in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.
Akorn Inc (AKRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Akorn Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akorn Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13
Oak Pharma Acquires Tafluprost Business from Merck 14
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15
Akorn Acquires Betimol, Opthalmic Drug, From Santen 16
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19
Partnerships 20
Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20
Knight Therapeutics Enters into Distribution Agreement with Akorn 21
Licensing Agreements 22
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22
Santen Pharma Enters into Licensing Agreement with Oak Pharma 23
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25
Asset Transactions 26
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26
Acquisition 28
Hi-Tech Pharma Acquires FormuTech Nutrition 28
Hi-Tech Pharma to Acquire Advanced Pharma 29
Akorn Acquires Excelvision for USD25.9 Million 30
Akorn Acquires VersaPharm from Tailwind Capital Partners 31
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33
Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34
Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36
Serum Institute Plans To Sell Its Stake In Akorn 38
Akorn Inc-Key Competitors 40
Akorn Inc-Key Employees 41
Akorn Inc-Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 43
Recent Developments 44
Financial Announcements 44
Nov 06, 2018: Akorn provides third quarter 2018 results 44
Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance 45
Legal and Regulatory 47
Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 47
Feb 26, 2018: Akorn Issues Statement on Investigation 48
Feb 09, 2018: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals Investors 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Figure
List of Figures
Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Akorn Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13
Oak Pharma Acquires Tafluprost Business from Merck 14
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15
Akorn Acquires Betimol, Opthalmic Drug, From Santen 16
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19
Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20
Knight Therapeutics Enters into Distribution Agreement with Akorn 21
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22
Santen Pharma Enters into Licensing Agreement with Oak Pharma 23
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26
Hi-Tech Pharma Acquires FormuTech Nutrition 28
Hi-Tech Pharma to Acquire Advanced Pharma 29
Akorn Acquires Excelvision for USD25.9 Million 30
Akorn Acquires VersaPharm from Tailwind Capital Partners 31
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33
Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34
Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36
Serum Institute Plans To Sell Its Stake In Akorn 38
Akorn Inc, Key Competitors 40
Akorn Inc, Key Employees 41
Akorn Inc, Subsidiaries 42
Akorn Inc, Joint Venture 43
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.